Natalia Bernardi Videira
Natalia Bernardi Videira has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina Migliorini Figueira
National Laboratory of Bioscience (LNBio), National Center of Research in Energy and Materials (CNPEM), Campinas 13083-100, Brazil
3 shared publications - Elma Omeragic
University of Sarajevo-Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina
2 shared publications - Julia M. L. Menon
Preclinicaltrials.eu, Netherlands Heart Institute
2 shared publications - Malgorzata Lagisz
Collaboration for Open Science and Synthesis in Ecology and Evolution (COSSEE), Department of Biological Sciences, Faculty of Science, University of Alberta, Edmonton, Canada
2 shared publications - Milica D. Pavlovic
Human Toxicology Program, Graduate College, University of Iowa
2 shared publications - Rebecca L. Morgan
School of Medicine, Case Western Reserve University
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Taylor & Francis in Evidence-Based Toxicology
- Vol. 4 (1)
Reporting quality of systematic review protocols in environmental and occupational toxicology: a meta-epidemiology study
- 30 October 2026
- Published by Taylor & Francis in Evidence-Based Toxicology
- Vol. 4 (1)
Open AccessReporting quality of systematic review protocols in environmental and occupational toxicology: a meta-epidemiology study
- Open Access
- 14 April 2025
- Published by Taylor & Francis in Evidence-Based Toxicology
- Vol. 3 (1)
Reporting quality of systematic review protocols in environmental and occupational toxicology: a meta-epidemiology study protocol
- 14 April 2025
- Published by Taylor & Francis in Evidence-Based Toxicology
- Vol. 3 (1)
Open AccessReporting quality of systematic review protocols in environmental and occupational toxicology: a meta-epidemiology study protocol
- Open Access
- 1 January 2025
- Published by MedCrave Group Kft. in Journal of Applied Biotechnology and Bioengineering
- Vol. 12 (2) , 78-79
Popularization and dissemination of biotechnology in Brazil
- 1 January 2025
- Published by MedCrave Group Kft. in Journal of Applied Biotechnology and Bioengineering
- Vol. 12 (2) , 78-79
Open AccessPopularization and dissemination of biotechnology in Brazil
- 23 October 2024
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 161 (16)
Exploring the molecular pathways of the activation process in PPARγ recurrent bladder cancer mutants
The intricate involvement of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in glucose homeostasis and adipogenesis is well-established. However, its role in cancer, particularly luminal bladder cancer, remains debated. The overexpression and activation of PPARγ are implicated in tumorigenesis. Specific gain-of-function mutations (M280I, I290M, and T475M) within the ligand-binding domain of PPARγ are associated with bladder cancer and receptor activation. The underlying molecular pathways prompted by these mutations remain unclear. We employed a dual-basin structure-based model (db-SBM) to explore the conformational dynamics between the inactive and active states of PPARγ and examined the effects of the M280I, I290M, and T475M mutations. Our findings, consistent with the existing literature, reveal heightened ligand-independent transcriptional activity in the I290M and T475M mutants. Both mutants showed enhanced stabilization of the active state compared to the wild-type receptor, with the I290M mutation promoting a specific transition route, making it a prime candidate for further study. Electrostatic analysis identified residues K303 and E488 as pivotal in the I290M activation cascade. Biophysical assays confirmed that disrupting the K303–E488 interaction reduced the thermal stabilization characteristic of the I290M mutation. Our study demonstrates the predictive capabilities of combining simulation and cheminformatics methods, validated by biochemical experiments, to gain insights into molecular activation mechanisms and identify target residues for protein modulation.
- 23 October 2024
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 161 (16)
Exploring the molecular pathways of the activation process in PPARγ recurrent bladder cancer mutants
The intricate involvement of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in glucose homeostasis and adipogenesis is well-established. However, its role in cancer, particularly luminal bladder cancer, remains debated. The overexpression and activation of PPARγ are implicated in tumorigenesis. Specific gain-of-function mutations (M280I, I290M, and T475M) within the ligand-binding domain of PPARγ are associated with bladder cancer and receptor activation. The underlying molecular pathways prompted by these mutations remain unclear. We employed a dual-basin structure-based model (db-SBM) to explore the conformational dynamics between the inactive and active states of PPARγ and examined the effects of the M280I, I290M, and T475M mutations. Our findings, consistent with the existing literature, reveal heightened ligand-independent transcriptional activity in the I290M and T475M mutants. Both mutants showed enhanced stabilization of the active state compared to the wild-type receptor, with the I290M mutation promoting a specific transition route, making it a prime candidate for further study. Electrostatic analysis identified residues K303 and E488 as pivotal in the I290M activation cascade. Biophysical assays confirmed that disrupting the K303–E488 interaction reduced the thermal stabilization characteristic of the I290M mutation. Our study demonstrates the predictive capabilities of combining simulation and cheminformatics methods, validated by biochemical experiments, to gain insights into molecular activation mechanisms and identify target residues for protein modulation.
- 30 August 2023
- Published by Wiley in Journal of Applied Toxicology
- Vol. 44 (2) , 216-234
The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits
Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these drugs are reported to be safe in a controlled environment (such as clinical trials), exposure to low doses of these drugs can result in psychedelic effects, and therefore, occupational safety is an important consideration to prevent adverse effects in the workplace from low daily exposure. This article will discuss the factors involved in the derivation of occupational exposure limits (OELs) and risk assessment of these psychedelic drugs. To support the OEL derivations of psychedelic drugs, information regarding their mechanism of action, adverse effect profiles, pharmacokinetics, clinical effects, and nonclinical toxicity were considered. Additionally, psilocybin and LSD, which are the most extensively researched psychedelic substances, are employed as illustrative examples in case studies. The OELs derived for psilocybin and for LSD are 0.05 and 0.002 μg/m3, respectively, which indicates that these are highly hazardous compounds, and it is important to take into account suitable safety measures and risk‐management strategies in order to minimize workplace exposure.
- 30 August 2023
- Published by Wiley in Journal of Applied Toxicology
- Vol. 44 (2) , 216-234
The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits
Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these drugs are reported to be safe in a controlled environment (such as clinical trials), exposure to low doses of these drugs can result in psychedelic effects, and therefore, occupational safety is an important consideration to prevent adverse effects in the workplace from low daily exposure. This article will discuss the factors involved in the derivation of occupational exposure limits (OELs) and risk assessment of these psychedelic drugs. To support the OEL derivations of psychedelic drugs, information regarding their mechanism of action, adverse effect profiles, pharmacokinetics, clinical effects, and nonclinical toxicity were considered. Additionally, psilocybin and LSD, which are the most extensively researched psychedelic substances, are employed as illustrative examples in case studies. The OELs derived for psilocybin and for LSD are 0.05 and 0.002 μg/m3, respectively, which indicates that these are highly hazardous compounds, and it is important to take into account suitable safety measures and risk‐management strategies in order to minimize workplace exposure.
- 1 March 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 484, 1-14
Modulation of nuclear receptor function: Targeting the protein-DNA interface
- 1 March 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 484, 1-14
Modulation of nuclear receptor function: Targeting the protein-DNA interface
- Open Access
- 12 April 2018
- Published by Wiley in PPAR Research
- Vol. 2018, 1-14
Cellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives
Peroxisome proliferator-activated receptor beta/delta (PPARß/δ) is considered a therapeutic target for metabolic disorders, cancer, and cardiovascular diseases. Here, we developed one pipeline for the screening of PPARß/δ agonists, which reduces the cost, time, and false-positive hits. The first step is an optimized 3-day long cellular transactivation assay based on reporter-gene technology, which is supported by automated liquid-handlers. This primary screening is followed by a confirmatory transactivation assay and by two biophysical validation methods (thermal shift assay (TSA) and (ANS) fluorescence quenching), which allow the calculation of the affinity constant, giving more information about the selected hits. All of the assays were validated using well-known commercial agonists providing trustworthy data. Furthermore, to validate and test this pipeline, we screened a natural extract library (560 extracts), and we found one plant extract that might be interesting for PPARß/δ modulation. In conclusion, our results suggested that we developed a cheaper and more robust pipeline that goes beyond the single activation screening, as it also evaluates PPARß/δ tertiary structure stabilization and the ligand affinity constant, selecting only molecules that directly bind to the receptor. Moreover, this approach might improve the effectiveness of the screening for agonists that target PPARß/δ for drug development.
- 12 April 2018
- Published by Wiley in PPAR Research
- Vol. 2018, 1-14
Open AccessCellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives
Peroxisome proliferator-activated receptor beta/delta (PPARß/δ) is considered a therapeutic target for metabolic disorders, cancer, and cardiovascular diseases. Here, we developed one pipeline for the screening of PPARß/δ agonists, which reduces the cost, time, and false-positive hits. The first step is an optimized 3-day long cellular transactivation assay based on reporter-gene technology, which is supported by automated liquid-handlers. This primary screening is followed by a confirmatory transactivation assay and by two biophysical validation methods (thermal shift assay (TSA) and (ANS) fluorescence quenching), which allow the calculation of the affinity constant, giving more information about the selected hits. All of the assays were validated using well-known commercial agonists providing trustworthy data. Furthermore, to validate and test this pipeline, we screened a natural extract library (560 extracts), and we found one plant extract that might be interesting for PPARß/δ modulation. In conclusion, our results suggested that we developed a cheaper and more robust pipeline that goes beyond the single activation screening, as it also evaluates PPARß/δ tertiary structure stabilization and the ligand affinity constant, selecting only molecules that directly bind to the receptor. Moreover, this approach might improve the effectiveness of the screening for agonists that target PPARß/δ for drug development.